- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 479712, 11 pages
Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene
1Department of Orthopaedics, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
2Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
3Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
Received 23 August 2011; Accepted 20 February 2012
Academic Editor: Quincy Chu
Copyright © 2012 Patrick J. Messerschmitt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. Surveillance and End Results (SEER) Program, SEER Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973–2005 varying)—Linked to County Attributes—Total U.S., 1969–2005, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2008.
- S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, pp. 776–790, 2002.
- A. M. Davis, R. S. Bell, and P. J. Goodwin, “Prognostic factors in osteosarcoma: a critical review,” Journal of Clinical Oncology, vol. 12, no. 2, pp. 423–431, 1994.
- P. J. Messerschmitt, R. M. Garcia, F. W. Abdul-Karim, E. M. Greenfield, and P. J. Getty, “Osteosarcoma,” Journal of the American Academy of Orthopaedic Surgeons, vol. 17, no. 8, pp. 515–527, 2009.
- P. A. Meyers, C. L. Schwartz, M. Krailo et al., “Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 2004–2011, 2005.
- A. J. Chou, E. S. Kleinerman, M. D. Krailo et al., “Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group,” Cancer, vol. 115, no. 22, pp. 5339–5348, 2009.
- P. A. Meyers, C. L. Schwartz, M. D. Krailo et al., “Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the children's oncology group,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 633–638, 2008.
- S. Kaap, I. Quentin, D. Tamiru, M. Shaheen, K. Eger, and H. J. Steinfelder, “Structure activity analysis of the pro-apoptotic, antitumor effect of nitrostyrene adducts and related compounds,” Biochemical Pharmacology, vol. 65, no. 4, pp. 603–610, 2003.
- J. H. Kim, J. H. Kim, G. E. Lee, J. E. Lee, and I. K. Chung, “Potent inhibition of human telomerase by nitrostyrene derivatives,” Molecular Pharmacology, vol. 63, no. 5, pp. 1117–1124, 2003.
- R. Mohan, N. Rastogi, I. N. N. Namboothiri, S. M. Mobin, and D. Panda, “Synthesis and evaluation of α-hydroxymethylated conjugated nitroalkenes for their anticancer activity: inhibition of cell proliferation by targeting microtubules,” Bioorganic & Medicinal Chemistry, vol. 14, no. 23, pp. 8073–8085, 2006.
- W. Y. Wang, P. W. Hsieh, Y. C. Wu, and C. C. Wu, “Synthesis and pharmacological evaluation of novel β-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity,” Biochemical Pharmacology, vol. 74, no. 4, pp. 601–611, 2007.
- W. Y. Wang, Y. C. Wu, and C. C. Wu, “Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-β-nitrostyrene, a novel tyrosine kinase inhibitor,” Molecular Pharmacology, vol. 70, no. 4, pp. 1380–1389, 2006.
- A. Levitzki and E. Mishani, “Tyrphostins and other tyrosine kinase inhibitors,” Annual Review of Biochemistry, vol. 75, pp. 93–109, 2006.
- P. J. Messerschmitt, A. N. Rettew, R. E. Brookover, R. M. Garcia, P. J. Getty, and E. M. Greenfield, “Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2168–2175, 2008.
- D. P. M. Hughes, D. G. Thomas, T. J. Giordano, K. T. McDonagh, and L. H. Baker, “Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition,” Pediatric Blood and Cancer, vol. 46, no. 5, pp. 614–623, 2006.
- P. J. Coopman and S. C. Mueller, “The Syk tyrosine kinase: a new negative regulator in tumor growth and progression,” Cancer Letters, vol. 241, no. 2, pp. 159–173, 2006.
- R. Rezzonico, A. Schmid-Alliana, G. Romey et al., “Prostaglandin E2 induces interaction between hSlo potassium channel and Syk tyrosine kinase in osteosarcoma cells,” Journal of Bone and Mineral Research, vol. 17, no. 5, pp. 869–878, 2002.
- S. Yanagi, R. Inatome, T. Takano, and H. Yamamura, “Syk expression and novel function in a wide variety of tissues,” Biochemical and Biophysical Research Communications, vol. 288, no. 3, pp. 495–498, 2001.
- A. Craxton, A. Jiang, T. Kurosaki, and E. A. Clark, “Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt,” Journal of Biological Chemistry, vol. 274, no. 43, pp. 30644–30650, 1999.
- Z. A. Stewart and J. A. Pietenpol, “Syk: a new player in the field of breast cancer,” Breast Cancer Research, vol. 3, no. 1, pp. 5–7, 2001.
- J. M. Bradshaw, “The Src, Syk, and Tec family kinases: distinct types of molecular switches,” Cellular Signalling, vol. 22, no. 8, pp. 1175–1184, 2010.
- M. Turner, E. Schweighoffer, F. Colucci, J. P. Di Santo, and V. L. Tybulewicz, “Tyrosine kinase SYK: essential functions for immunoreceptor signalling,” Immunology Today, vol. 21, no. 3, pp. 148–154, 2000.
- R. H. Alvarez, H. M. Kantarjian, and J. E. Cortes, “The role of Src in solid and hematologic malignancies: development of new-generation src inhibitors,” Cancer, vol. 107, no. 8, pp. 1918–1929, 2006.
- P. Hingorani, W. Zhang, R. Gorlick, and E. A. Kolb, “Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo,” Clinical Cancer Research, vol. 15, no. 10, pp. 3416–3422, 2009.
- A. C. Shor, E. A. Keschman, F. Y. Lee et al., “Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival,” Cancer Research, vol. 67, no. 6, pp. 2800–2808, 2007.
- L. L. Worth, S. F. Jia, Z. Zhou, L. Chen, and E. S. Kleinerman, “Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases,” Clinical Cancer Research, vol. 6, no. 9, pp. 3713–3718, 2000.
- H. H. Luu, Q. Kang, K. P. Jong et al., “An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis,” Clinical and Experimental Metastasis, vol. 22, no. 4, pp. 319–329, 2005.
- X. Duan, S. F. Jia, Z. Zhou, R. R. Langley, M. F. Bolontrade, and E. S. Kleinerman, “Association of αvβ3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells,” Clinical and Experimental Metastasis, vol. 21, no. 8, pp. 747–753, 2005.
- S. F. Jia, L. L. Worth, and E. S. Kleinerman, “A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies,” Clinical and Experimental Metastasis, vol. 17, no. 6, pp. 501–506, 1999.
- R. A. Blake, M. A. Broome, X. Liu et al., “SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling,” Molecular and Cellular Biology, vol. 20, no. 23, pp. 9018–9027, 2000.
- J. Y. Q. Lai, P. J. Cox, R. Patel et al., “Potent small molecule inhibitors of spleen tyrosine kinase (Syk),” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 18, pp. 3111–3114, 2003.
- H. Hisamichi, R. Naito, A. Toyoshima et al., “Synthetic studies on novel Syk inhibitors. Part 1: synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives,” Bioorganic & Medicinal Chemistry, vol. 13, no. 16, pp. 4936–4951, 2005.
- N. Yamamoto, K. Takeshita, M. Shichijo et al., “The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 1174–1181, 2003.
- V. Betapudi, L. S. Licate, and T. T. Egelhoff, “Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration,” Cancer Research, vol. 66, no. 9, pp. 4725–4733, 2006.
- M. L. Edin, A. K. Howe, and R. L. Juliano, “Inhibition of PKA blocks fibroblast migration in response to growth factors,” Experimental Cell Research, vol. 270, no. 2, pp. 214–222, 2001.
- J. C. Dai, P. He, X. Chen, and E. M. Greenfield, “TNFα and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics,” Bone, vol. 38, no. 4, pp. 509–520, 2006.
- J. Bain, L. Plater, M. Elliott et al., “The selectivity of protein kinase inhibitors: a further update,” Biochemical Journal, vol. 408, no. 3, pp. 297–315, 2007.
- A. N. Rettew, P. J. Getty, and E. M. Greenfield, “Novel receptor tyrosine kinases in osteosarcoma identified by phosphoproteomic and functional genomic screening,” in Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, USA, April 2010.
- N. Milhazes, R. Calheiros, M. P. M. Marques et al., “β-Nitrostyrene derivatives as potential antibacterial agents: a structure-property-activity relationship study,” Bioorganic & Medicinal Chemistry, vol. 14, no. 12, pp. 4078–4088, 2006.
- R. K. Pettit, G. R. Pettit, E. Hamel et al., “E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory β-E-nitrostyrenes,” Bioorganic & Medicinal Chemistry, vol. 17, no. 18, pp. 6606–6612, 2009.
- Y. M. McNamara, S. M. Cloonan, A. J. S. Knox et al., “Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents,” Bioorganic & Medicinal Chemistry, vol. 19, no. 3, pp. 1328–1348, 2011.
- A. H. Walsh, A. Cheng, and R. E. Honkanen, “Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A,” FEBS Letters, vol. 416, no. 3, pp. 230–234, 1997.
- J. M. Werner, K. Eger, and H. Jürgen Steinfelder, “Comparison of the rapid pro-apoptotic effect of trans-β-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells,” Apoptosis, vol. 12, no. 1, pp. 235–246, 2007.
- X. Deng, T. Ito, B. Carr, M. Mumby, and W. S. May Jr., “Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A,” Journal of Biological Chemistry, vol. 273, no. 51, pp. 34157–34163, 1998.
- N. W. Kim, M. A. Piatyszek, K. R. Prowse et al., “Specific association of human telomerase activity with immortal cells and cancer,” Science, vol. 266, no. 5193, pp. 2011–2015, 1994.